ArticleF1000Research2017
Yellow fever in the Americas: the growing concern about new epidemics.
Article in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Yellow fever virus infection in non-human primates: a systematic review and meta-analysis of prevalence, seroprevalence, and epizootic case reports (1950-2025).Frontiers in veterinary science · 2026Pooled it
- Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.Arthritis research & therapy · 2019Trial
- Colombian protocol for the hospital management of non-critically ill patients with suspected or confirmed yellow fever.New microbes and new infections · 2026Review
- Characterization of an Unusual Severe Yellow Fever Outbreak in the Colombian Andean Region.Open forum infectious diseases · 2026Article
- Revisiting the Status of Yellow Fever Epizootics and Its Surveillance in South America: New Non-Human Primates, Spillover and Ecological Drivers.Pathogens (Basel, Switzerland) · 2026Review
- Review
- Yellow fever in older adults: an overlooked high-risk population in South American outbreaks.Sustainable microbiology · 2026Article
- Colombian consensus on the care of critically ill patients with suspected or confirmed severe yellow fever.Lancet regional health. Americas · 2025Review
- Yellow fever in Putumayo, Colombia, 2024.New microbes and new infections · 2025Article
- Article
- A safer cell-based yellow fever live attenuated vaccine protects mice against YFV infection.iScience · 2024Article
- Yellow Fever: Global Impact, Epidemiology, Pathogenesis, and Integrated Prevention Approaches.Le infezioni in medicina · 2024Review
- Multidisciplinary approach for surveillance and risk identification of yellow fever and other arboviruses in Colombia.One health (Amsterdam, Netherlands) · 2022Article
- Mapping and Validation of Peptides Differentially Recognized by Antibodies from the Serum ofViruses · 2022Article
- Changing epidemiology of yellow fever virus in Oyo State, Nigeria.BMC public health · 2022Article
- Review
- Yellow fever virus outbreak in Brazil under current and future climate.Infectious Disease Modelling · 2021Article
- Understanding Asthma and Allergies by the Lens of Biodiversity and Epigenetic Changes.Frontiers in immunology · 2021Review
- The Constant Threat of Zoonotic and Vector-Borne Emerging Tropical Diseases: Living on the Edge.Frontiers in tropical diseases · 2021Article
- Re-Emergence of Yellow Fever in Brazil during 2016-2019: Challenges, Lessons Learned, and Perspectives.Viruses · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yellow fever (YF) is a haemorrhagic viral disease with a high case fatality rate. It is considered a reemerging infectious disease of remarkable importance. During the last outbreaks in Brazil (2016-2017), many cases of YF emerged despite high YF vaccination coverage in some areas. However, there are many areas and populations worldwide where vaccination coverage has been low for years (e.g. Nigeria), which increases the risk of major epidemics in such areas, as would be the case in many of the American territories. Several factors, including the vast border and migratory status of Brazil, the widespread distribution of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.